Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion
Innovent Biologics rose as much as 10%, after entering a strategic global licensing and collaboration agreement with Pfizer to develop oncology medicines.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
